Vemircopan (ALXN2050) Monotherapy in Paroxysmal Nocturnal ...
WEBNov 15, 2022 · A latter oral factor D inhibitor, ALXN2050 (vemircopan), has the same mechanism of action as danicopan but demonstrates increased potency and binding affinity for factor D. It also achieves immediate, complete, and sustained AP inhibition with twice-daily administration (BID).
Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or ...
WEBThis is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of ALXN2050 (120 and 180 milligrams [mg]) in addition to background therapy consistent with the standard of care in adult participants (≥ 18 to ≤ 75 years of age) with either LN or IgAN.
Home - ClinicalTrials.gov
WEBWe would like to show you a description here but the site won’t allow us.
Clinical Trial Alert: Phase 2 Study of ALXN2050 in Adults Living …
WEBApr 6, 2022 · Researchers at Alexion Pharmaceuticals are seeking adults living with generalized myasthenia gravis (gMG) to participate in a phase 2 clinical trial to evaluate the safety, effectiveness, and pharmacological properties of the investigational drug ALXN2050.
Vemircopan - Alexion AstraZeneca Rare Disease - AdisInsight
WEBJun 21, 2024 · Vemircopan (formerly ALXN 2050 and ACH 0145228) is a second generation complement factor D inhibitor, being developed by Alexion AstraZeneca Rare Disease (a.
Pipeline - AstraZeneca
WEBAstraZeneca’s deep pipeline of medicines focusing on their key therapeutic areas.
Clinical Trial Alert: Phase 2 Study of ALXN2050 in Adults with ...
WEBMar 9, 2023 · Researchers at Alexion AZ Rare Disease are seeking adults living with generalized myasthenia gravis (gMG) to participate in a phase 2 clinical trial (ExpanD Study) to evaluate the safety and efficacy of ALXN2050 (vemircopan) to treat gMG.
WCN23-0141 A PHASE 2 STUDY EVALUATING THE EFFICACY AND …
WEBMar 1, 2023 · This global, multicenter, phase 2 study (NCT05097989) will evaluate the efficacy and safety of ALXN2050, an oral, small molecule complement factor D inhibitor, in adults with IgA nephropathy or LN. Methods. Key study design elements and endpoints are shown in the Figure.
Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or ... - ICH …
WEBOct 18, 2021 · July 17, 2024 updated by: Alexion Pharmaceuticals, Inc. A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Alexion dumps ex-Achillion C3G program after seeing phase 2 …
WEBJul 30, 2020 · Alexion struck the deal after seeing midphase proof-of-concept data on ALXN2040 in PNH as well as proof-of-mechanism evidence in C3G from a trial of six subjects.
Skip to content